ZYME
USDZymeworks Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$18.390
High
$18.770
Low
$18.000
Volume
0.08M
Company Fundamentals
Market Cap
1.4B
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.66M
Exchange
NMS
Currency
USD
52-Week Range
Related News
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall
HC Wainwright & Co. Upgrades Zymeworks to Buy, Raises Price Target to $26
HC Wainwright & Co. analyst Robert Burns upgrades Zymeworks from Neutral to Buy and raises the price target from $13 to $26.
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung
B. Riley Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $30
B. Riley Securities analyst Mayank Mamtani initiates coverage on Zymeworks with a Buy rating and announces Price Target of $30.
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
Related Stocks
AGNCL
AGNC Investment Corp. Depositary Shares Each Representing a 1/1000th Interest in a Share of 7.75% Series G Fixed-Rate Reset Cumulative Redeemable Preferred Stock
TMO
Thermo Fisher Scientific
GOOD
Gladstone Commercial Corporation Real Estate Investment Trust
ENTO
Entero Therapeutics Inc.
INO
Inovio Pharmaceuticals Inc.
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.